Community/Retail

The pharmacist’s role is transforming from product management to clinical specialization.

A global trial found the long-acting analogue reduced severe hypoglycemia and nighttime lows in youth with type 1 diabetes by 12 months, not 6.

As 2026 wildfire smoke from Canada blankets the US, pharmacists can facilitate early refills, counsel on protective measures, and help patients understand when worsening symptoms require emergency care.

New scientific statement links moderate caffeine to lower cardiovascular risk—but flags energy drinks as a distinct hazard pharmacists should counsel on.

Robert J. DiDomenico, PharmD, FAHA, discusses the new AHA scientific statement on identifying and safely deprescribing unnecessary medications in patients with cardiovascular disease.

Pharmacist outreach at VA doubles SGLT2 inhibitor starts in diabetes and CKD, helping close cardiorenal guideline gaps.

Pharmacists’ individual knowledge of patient circumstances can be their greatest tool.

CGRP drugs and new PACAP targets are reshaping acute and preventive therapy.

A new toxicological risk assessment builds on 2024 findings that raised consumer concern, offering pharmacists reassuring data to share with patients.

Framing medications as common and normal improved patients' willingness to start therapy, whereas numerical adverse effect data had no significant impact.

A machine learning–triggered nephrology consultation did not reduce peak creatinine changes in hospitalized patients at high risk for stage 2 AKI.

Understanding OTC oral and topical treatment options, plus lifestyle steps, helps pharmacists guide safer relief.

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

Nephrology experts Ashish Verma, MBBS, and Sophie Claudel, MD, discuss why estimated glomerular filtration rate alone misses chronic kidney disease and how pharmacists can help drive earlier detection.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

Two clinicians—a psychiatric prescriber and a hospital clinical pharmacist—weigh in on when to add a glucagon-like peptide-1 receptor agonist for patients with serious mental illness, how to monitor for trouble, and how to set expectations at the counter.

This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.

AI functions as a supportive layer that improves efficiency while preserving the pharmacist’s central role in therapeutic decision-making.

A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

Prepare your pharmacy for flu season with updated vaccine formulations, screening, staffing, ordering, cold-chain controls, billing workflows, and patient outreach to boost vaccination uptake.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

A simplified, no-cost machine learning version of the Martin-Hopkins equation matched the original's accuracy across millions of blood samples, helping clinicians identify patients who qualify for lipid-lowering therapy.

Get engaged or get left out.

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

Case counts will likely continue to rise as reporting catches up with the incubation lag.

This FAQ breaks down which drugs are covered by the program, who qualifies, how to process claims correctly, and what pharmacists need to know to counsel patients through this landmark shift in obesity drug access.